Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
Hope S Rugo*, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N Schwartz, Timothy J Pluard, Francesco Ricci, William R Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de BoerSung-Bae Kim, Katarína Petráková, Denise A Yardley, Orit Freedman, Erik H Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A Fasching, Peter A Kaufman, Emily J Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J Gradishar, SOPHIA Study Group
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial'. Together they form a unique fingerprint.